Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer

This study has been completed.
Sponsor:
Information provided by:
University of Iowa
ClinicalTrials.gov Identifier:
NCT00245349
First received: October 25, 2005
Last updated: June 9, 2008
Last verified: June 2008
  Purpose

Preliminary observations suggest positron emission tomography (PET) imaging with an F-18 labeled thymidine analog (FLT) can selectively identify proliferating and non-proliferating tissues, including tumors. FLT uptake in the tumor appears to reflect the level of cells undergoing DNA synthesis. This is clinically important because cell proliferation markers have significant prognostic value, both prior to initiating radiotherapy and as they change during the course of therapy. In the proposed study, the researchers assess the biodistribution and radiation dosimetry of FLT to obtain the necessary data to file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The information collected under Radioactive Drug Research Committee (RDRC) approval will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management of the subject.


Condition Intervention Phase
Head and Neck Cancer
Procedure: F-18 Fluorothymidine
Phase 1

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biodistribution and Radiation Dosimetry of F-18 Fluorothymidine (FLT) Imaged With Positron Emission Tomography (PET) in Patients With Head and Neck Cancer: A Radioactive Drug Research Committee (RDRC) Study

Resource links provided by NLM:


Further study details as provided by University of Iowa:

Biospecimen Retention:   Samples With DNA

Tumor biopsy, blood samples


Enrollment: 9
Study Start Date: October 2005
Study Completion Date: April 2008
Groups/Cohorts Assigned Interventions
FLT
Study group receiving FLT for imaging
Procedure: F-18 Fluorothymidine

Detailed Description:

There are approximately 40,000 new cases of head and neck cancer each year in the United States. Worldwide more than 500,000 individuals will develop head and neck cancer each year, ranking as the sixth most common cancer. These cancers are predominately squamous cell cancers. Approximately two thirds of subjects will present with locally advanced disease with either large disease at the primary site and/or spread to regional lymph node levels.

Despite aggressive treatment, 5-year survival remains poor (overall, approximately 50%). The major site of treatment failure is within the head and neck region, with distant metastases occurring in approximately 25% of subjects and usually after local and/or regional (nodal) failure.

Current treatment options for locally advanced head and neck cancer include combinations of surgery, radiation therapy, and chemotherapy. It is currently difficult to predict which combination will be best suited for any particular individual. Rapid methods of assessing the response of subjects to chemo-radiotherapy would be a useful tool, as it would permit the oncologist to change therapies, either in type or degree, in cases when the subject does not respond to the initial therapy regimen. Current best methods of evaluating tumor response are either serial CT examinations, so that changes in tumor size can be estimated or a fluorodeoxyglucose (FDG) positron emission tomography (PET) study in which changes in the metabolic status of the tumor are evaluated. Unfortunately, the anatomic information afforded by CT examinations often require months after treatment to allow the full effects of therapy to take place. Even after this time, the metabolic activity of any remaining tissue is nearly impossible to assess by CT scan, making it difficult to distinguish between fibrosis and viable tissue. Generally the FDG studies require 3-4 weeks after the end of the therapeutic regime before the relevant information is available, with more reliable information obtained at 3-4 months after treatment.

It is predictable that the most immediate signal of an anti-tumor therapeutic regime that has been successful is that the tumor cells will stop dividing (proliferating) after the therapy is initiated. Therefore, a tracer which is taken up into and retained in cells as a function of their proliferative activity should provide rapid information as to the effectiveness of the treatment. It is the objective of this study to determine the biodistribution and radiation dosimetry of tracer F-18 3`-deoxy-3`-fluorothymidine. This distribution data is essential before an Investigational New Drug (IND) application can be filed with the FDA that would allow the use of this tracer in clinical trials.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Head & Neck Cancer

Criteria

Inclusion Criteria:

  1. Ability to understand and willingness to sign a written informed consent document.
  2. Subject must have histologically confirmed stage III, or IV squamous cell carcinoma of the head and neck whose primary origin was from the oral cavity, oropharynx, hypopharynx, or larynx. Carcinoma must be staged using the American Joint Committee on Cancer (AJCC) staging criteria version 6. Adequate tumor must be amenable to biopsy via outpatient methods, therefore the majority of subjects will be those with oropharyngeal lesions.
  3. Subjects must be scheduled to receive combined chemo-radiotherapy treatment for their standard cancer care. Treatment decisions will be made by the treating otolaryngologist, radiation, and medical oncologists.
  4. Males or females greater than or equal to 21 years of age. Squamous cell cancer of the head and neck is exceedingly rare in children and not generally applicable to the pediatric population.
  5. Karnofsky score greater than or equal to 60% at time of screening.
  6. Life expectancy of greater than 6 months.
  7. Subject must have normal organ and marrow function as defined below:

    • leukocytes greater than or equal to 3,000/microL
    • absolute neutrophil count greater than or equal to 1,500/microL
    • platelets greater than or equal to 100,000/microL
    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal
    • creatinine within normal institutional limits
    • BUN within normal institutional limits
    • PT and PTT < 2.0 X upper normal limits
  8. The effects of FLT on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A screening urine hCG will be administered to women of childbearing potential before each FLT scan.

Exclusion Criteria:

  1. Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  2. Subject may not be receiving any other investigational agents.
  3. Subject with a Karnofsky score below 60.
  4. Pregnant women are excluded from this study. FLT PET has the potential for teratogenic effects. Because there are potentially unknown risks for adverse events in nursing infants secondary to treatment of the mother with FLT, breastfeeding should be discontinued if the mother is imaged with FLT and may not resume for 48 hours after the FLT imaging.
  5. Subject with an inadequate marrow reserve as determined by history and/or the above tests.
  6. Subject with a bleeding or clotting dysfunction as determined by medical history and above tests.
  7. Subjects taking nucleoside analog medications such as those used as antiretroviral agents.
  8. Inadequate tumor volume to allow for 2 biopsies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00245349

Locations
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
Investigators
Principal Investigator: Yusuf Menda, MD University of Iowa, Department of Radiology-Nuclear Medicine
Principal Investigator: Kenneth J Dornfeld, MD, PhD University of Iowa
Principal Investigator: Timothy Tewson, PhD University of Iowa, Department of Radiology-Nuclear Medicine
  More Information

No publications provided

Responsible Party: Yusuf Menda, M.D., University of Iowa Hospitals & Clinics
ClinicalTrials.gov Identifier: NCT00245349     History of Changes
Other Study ID Numbers: 200502799
Study First Received: October 25, 2005
Last Updated: June 9, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Iowa:
Head and Neck cancer
Squamous cell carcinoma
FLT
Fluorothymidine
F-18

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on July 20, 2014